Argenx SE (ARGX), a leading force in biotechnology, has seen numerous events impact its operation and market performance. A significant development is the
FDA signaling a priority review for
Vyvgart, resulting in bolstered sentiments towards the company. As Vyvgart gains traction, argenx CEO has handed over the company operations to Karen Massey, the present operating chief. Also, despite a recent phase 3 trial setback regarding
efgartigimod SC for thyroid eye disease, Vyvgart sales have outperformed expectations across MG and CIDP treatments. Alongside, Wells Fargo analyst shows optimism for Argenx and has increased the PT to $1,317. Amid these occurrences, Argenx announced a collaboration with tennis legend Monica Seles to raise awareness of Myasthenia Gravis. Furthermore, the company is expanding its footprint in immunology by signing a $1.5B pact with Unnatural Products to convert macrocyclic peptides into 'undruggable' targets. Despite minor setbacks, the company's valuation reveals a significantly robust standing in the biotech market, reflecting investors' high confidence.
argenx News Analytics from Tue, 10 Jun 2025 07:00:00 GMT to Sat, 31 Jan 2026 14:36:03 GMT -
Rating 8
- Information 9
- Rumor -4
